Human tuberculosis caused by Mycobacterium microti is rare, but its prevalence and clinical significance may have been underestimated. To the best of our knowledge, 21 cases have been reported in the literature in the last decade. We report six recent pulmonary cases caused by M. microti over a period of 5 years detected in French clinical mycobacteriology laboratories of the hospital network. Our data confirm the potential of M. microti to cause clinical illness in immunocompetent patients. M. microti grew slowly from specimens, delaying the final microbiological diagnosis. Therefore, patients with tuberculosis caused by M. microti could benefit from the use of rapid diagnostic molecular techniques directly on clinical samples. From a review of the literature and this study, a classical antituberculous therapy seems effective in treating patients with M. microti disease.
Introduction
Mycobacterium microti belongs to the Mycobacterium tuberculosis complex (MTBC), a group that includes M. tuberculosis, Mycobacterium bovis, Mycobacterium africanum, 'Mycobacterium canettii', Mycobacterium pinnipedii and Mycobacterium caprae, the main agents of human and animal tuberculosis. M. microti's natural hosts and reservoirs are small rodents such as voles, shrews and wood mice. Sporadic cases of infection by M. microti have also been reported in other animals, such as cats, llamas, dogs, pigs, ferrets, badgers and a cow . M. microti was considered an unimportant pathogen for humans until 1998, when the first case of human pulmonary tuberculosis was reported . During the last decade, 20 additional cases of human infection have been reported in 10 other publications (de Jong et al., 2009; Emmanuel et al., 2007; Foudraine et al., 1998; Frank et al., 2009; Geiss et al., 2005; Horstkotte et al., 2001; Jenkins et al., 2006; Kremer et al., 1998; Niemann et al., 2000; van Soolingen et al., 1998) .
Case reports
Here we report for the first time 6 cases of human pulmonary tuberculosis caused by M. microti in France and review the other 21 cases from the literature. Six clinical strains of M. microti were isolated from the respiratory specimens of six patients over a period of 5 years (2002) (2003) (2004) (2005) (2006) (2007) in French clinical mycobacteriology laboratories of the university hospital network, non-university hospitals and a specialized private laboratory (Biomnis, Lyon, France). All these strains were referred to the Mycobacteria Reference Laboratory at the Pasteur Institute (Paris, France). Diagnosis of pulmonary tuberculosis due to M. microti was established when mycobacteria were identified as M. microti by two complementary molecular methods, GenoType MTBC (Hain Lifescience) and spoligotyping (Brudey et al., 2006) . The genetic diversity of the isolates was also explored by 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) typing. The medical records of the six patients were recovered retrospectively. Patient data included demographic characteristics, clinical symptomology, co-morbidities, treatment and outcome. Microbiological documentation of M. microti was abstracted as follows: presence of acid-fast bacilli on smears, time of growth detection of mycobacteria on both solid (Coletsos) and liquid media (MGIT BACTEC 960; Becton Dickinson), and antibiotic susceptibility.
We performed a comprehensive search of the literature in the Medline database from 1966 to 2009 using the following key terms: 'Mycobacterium microti', 'Mycobacterium microti pulmonary tuberculosis' and 'Mycobacterium microti human infection'. A second search was performed using the references included in the articles found from the initial search. We identified a total of 10 articles reporting 21 cases of human infection due to M. microti (de Jong et al., 2009; Emmanuel et al., 2007; Foudraine et al., 1998; Frank et al., 2009; Geiss et al., 2005; Horstkotte et al., 2001; Jenkins et al., 2006; Kremer et al., 1998; Niemann et al., 2000; van Soolingen et al., 1998) .
During the 5 year period under study, six patients were diagnosed with pulmonary tuberculosis caused by M. microti in France. The median age of patients was 40.3 years (range 29-61 years). There were four males and two females, all born in France. For the six patients, tuberculosis in their childhood or among their friends and family could not be proved. None of the patients was particularly exposed to pets, especially cats or small rodents. Two patients had underlying conditions such as diabetes mellitus.
The median time between the onset of clinical symptoms and the diagnosis of tuberculosis was 24.8 weeks (range 24-32 weeks). Presenting symptoms were a productive cough in six patients, night sweats in two, weight loss in five, fever in one and haemoptysis in one. Chest radiographs revealed upper-lobe cavitating pulmonary lesions in all six patients (four unilateral and two bilateral).
For the six patients, sputum smear microscopy showed acid-fast bacilli, and M. microti was isolated from at least one respiratory sample. M. microti grew on solid egg media only for one patient, in liquid medium only for two patients and in both media for three patients. The mean time of culture positivity was 48 days (range 42-58 days). All the isolates were sensitive to isoniazid, rifampicin, ethambutol and streptomycin by the proportion method in liquid medium (MGIT BACTEC 960). Three of the six isolates were sensitive to pyrazinamide, one was resistant and the results were inconclusive for two. A commercial reverse hybridization and multiplex line probe assay, GenoType MTBC (Hain Lifescience), identified the six strains as M. microti. Additionally, all the strains showed M. microti-specific signatures by spoligotyping. The spoligotype of two strains has already been described as ST641 in the international spoligotyping database SpolDB4 (Brudey et al., 2006) , whereas the spoligotypes of four strains were not found to have been described (Table 1) . Four patients were initially treated with a combination of four antituberculous drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) and one patient with a triple therapy (rifampicin, isoniazid and pyrazinamide) for a mean duration of 10 months. All six patients were cured on completion of the regimen and no relapse had been reported as of May 2010.
Discussion
M. microti tuberculosis is uncommon in humans. To the best of our knowledge, this description of six pulmonary cases is the first and largest series ever reported in the literature and brings to 27 the number of reported cases in both human immunodeficiency virus (HIV)-positive and -negative patients. Overall, the location of tuberculosis was predominantly pulmonary (19 cases) and uncommonly extrapulmonary (2 intra-abdominal and 1 osteomyelitis of the hip) (de Jong et al., 2009; Emmanuel et al., 2007; Foudraine et al., 1998; Frank et al., 2009; Geiss et al., 2005; Horstkotte et al., 2001; Jenkins et al., 2006; Kremer et al., 1998; Niemann et al., 2000; van Soolingen et al., 1998) . The location was not indicated in five cases (de Jong et al., 2009; Emmanuel et al., 2007; Foudraine et al., 1998; Frank et al., 2009; Geiss et al., 2005; Horstkotte et al., 2001; Jenkins et al., 2006; Kremer et al., 1998; Niemann et al., 2000; van Soolingen et al., 1998 Our data may suggest the potential of M. microti to cause clinical illness in immunocompetent patients. Among the 27 cases, 10 patients did not present any known immunological deficiencies (for which relevant clinical details were available). Among 11 other patients, tuberculosis was associated with HIV infection (4 cases), kidney transplantation (2 cases) and diabetes (5 cases). Indeed, recently, Restrepo et al. (2008) suggested that diabetes could be associated with an altered immune response to M. tuberculosis.
Specimen smear-microscopy was positive in most of the patients (22/27), and 7 presented cavitating lung lesions with positive direct smears. However, M. microti grew slowly from specimens (median 50.30 days; range 42-58), delaying the final microbiological diagnosis. Therefore, patients with tuberculosis caused by M. microti with specimens rich in acid-fast bacilli could benefit from the use of rapid diagnostic molecular techniques (such as spoligotyping or GenoType MTBC) directly on clinical samples. This rapid diagnosis could help prevent erroneous clinical diagnoses, inadequate treatments and movement of potentially contagious patients.
The ecological niche of M. microti remains unclear, although it is a recognized pathogen for wild rodents and occasionally for pets such as dogs or cats. Little is known about the incidence and ecology of M. microti infection in farm and other domestic animals . Several studies have described a high prevalence of M. microti infection in wild rodents, suggesting that these animals could be its reservoir. Zoonotic transmission could occur directly from rodents to humans, via domestic hosts such as cats or pet ferrets , or by contact with animal-contaminated environmental samples. However, zoonotic transmission investigations in most of the human cases were unsuccessful in tracing back the patient's potential infection source. Human-to-human transmission of M. microti has been suggested from secondary cases based on purified protein derivative skin testing , but it has never been proven by DNA fingerprinting. Therefore, the source of human infections remains unknown. Based on MIRU-VNTR fingerprinting (data not shown), our results indicate a lack of a genetic link between the six strains of M. microti isolated from patients in France, which excludes an epidemiological link among these patients.
Successful treatment of M. microti lung disease included several weeks of triple or quadruple antituberculous therapy. Among 19 patients with pulmonary tuberculosis, only 1 with a background of full-blown AIDS had a fatal outcome. Among the 27 cases of M. microti infection from the literature, death due to lethal Landouzy septicaemia was also reported in an elderly immunocompetent patient (Geiss et al., 2005) . Among the cases reviewed here, M. microti was susceptible to isoniazid, rifampicin, ethambutol and streptomycin. However, drug resistance and in vitro susceptibility interpretation problems were noted for pyrazinamide in three and two isolates, respectively, in this series. From a review of the literature, antituberculous therapy including isoniazid, rifampicin and ethambutol was successful, which indicates that regular antituberculous therapy with or without associated pyrazinamide is effective in treating patients with M. microti disease.
Comparative genomics has demonstrated that the genome of M. microti partially or completely lacks several genes of the RD1 region that are essential for virulence in other members of the MTBC (Brodin et al., 2002) . Indeed, in the past, several trials of M. microti as a vaccine led to the conclusion that it had a lack of virulence in immunocompetent humans. Although human pulmonary tuberculosis caused by M. microti is uncommon, our report together with the literature review suggest that the natural deletion of the RD1 region alone does not appear to alter the pathogenic capacity of M. microti. Its prevalence and clinical importance may have been underestimated, either because of the difficulties of primary isolation and differentiation of M. microti within the MTBC, or because of a lack of clinical differences between M. microti and M. tuberculosis pulmonary tuberculosis. However, other than in known immunocompromised patients developing M. microti infection, we cannot exclude that other genetic or immunological factors were predisposing the patient to mycobacterial infections. Additional studies using molecular methods remain necessary to clarify the real impact of M. microti in the epidemiology of human tuberculosis: (i) systematic molecular identification of MTBC species from human, wild (small rodents) and domestic animal (cats) strains in France; (ii) study and comparison of the genetic diversity of M. microti in animal (wild and domestic) and human compartments, and identification of the transmission within and between compartments (e.g. generalist and specialized genotypes).
